Download PDF
CC BY-NC-ND 4.0 · International Journal of Epilepsy 2016; 03(01): 028-032
DOI: 10.1016/S2213-6320(16)30023-9
Valproic Acid
Thieme Medical and Scientific Publishers Private Ltd.

Valproic Acid: A Summary of Indian Epilepsy Society-Consensus Document

Man Mohan Mehndiratta
a   Janakpuri Super Speciality Hospital, New Delhi
,
Sanjeev V. Thomas
b   Sree Chitra Tirunal Institute for Medical Sciences and Technology, Thiruvananthapuram
,
Neeraj N. Baheti
c   Central India Institute of Medical Sciences, Nagpur 440010, Maharashtra
,
Atma Ram Bansal
d   Medanta—The Medicity Gurgaon, Haryana
,
Sanjeev Bhoi
e   Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow
,
Deepanshu Dubey
e   Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow
,
Sheffali Gulati
f   All India Institute of Medical Sciences, New Delhi
,
Satish Jain
g   Director, Indian Epilepsy Centre, New Delhi
,
Sita Jayalakshmi
h   Krishna Institute of Medical Sciences, Secunderabad, Telangana
,
Jayantee Kalita
e   Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow
,
Parampreet S. Kharbanda
i   Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh
,
Chanda Kulkarni
j   SAKRA World Hospital, Bangalore, India
,
Bindu Menon
k   Apollo Speciality Hospitals, Nellore
,
Usha Kant Misra
e   Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow
,
P. Satishchandra
l   National Institute of Mental Health & Neuro Sciences (NIMHANS), Bengaluru, Karnataka
,
Vinod S. Saxena
m   Life Trustee Indian Epilepsy Association – 18th International Epilepsy Congress Trust, Delhi
,
Suvasini Sharma
n   Lady Hardinge Medical College and Associated Kalawati Saran Children's Hospital, New Delhi
,
Gagandeep Singh
o   Dayanand Medical College, Ludhiana
,
Sanjib Sinha
p   NIMHANS, Banglore
,
Manjari Tripathi
f   All India Institute of Medical Sciences, New Delhi
,
Sudhindra Vooturi
q   Krishna Institute of Medical Sciences, Minister Road, Secunderabad - 03, Telangana, India
,
Nandan Yardi
r   BJ Medical College (MUHS), Pune
› Author Affiliations
Further Information

Publication History

Publication Date:
06 May 2018 (online)

   Permissions and Reprints

Introduction

Valproic acid (VPA) is a well established anticonvulsant drug for the last 40 years and is now a part of more than 130 national health care programmes. Since 1988, it has regularly featured as an anticonvulsant in the WHO Model List of Essential Medicines [[1]]. The current NICE Guidelines recommend Valproic Acid as the first-line of treatment for Idiopathic Generalized Epilepsies (IGEs) in children, young people and adults but should be used with caution in pregnant women. [[2]]

 

  • References

  • 1 WHO List of Essential Medicines. CH1211. Geneva, Switzerland: 2015: 5
    Google Scholar
  • 2 Nunes VD, Sawyer L, Neilson J, Sarri G, Cross JH. Diagnosis and management of the epilepsies in adults and children: Summary of updated NICE guidance. BMJ 2012; 344: e281
    CrossrefPubMedGoogle Scholar
  • 3 Ahamed wb, Carmody h. Safe use of sodium valproate. Aust Prescr 2014; 37: 124-127
    CrossrefPubMedGoogle Scholar
  • 4 McNamara JC. Chapter 19. Pharmacotherapy of epilepsies. In: Brunton LL, Lazo JS, Parker KL. eds. In: Goodman & Gilman's The Pharmacological Basis of Therapeutics. 11th. Edition New York: The McGrwa-Hill Companies Inc; 2005
    Google Scholar
  • 5 Large CH, Kalinichev M, Lucas A. et al. The relationship between sodium channel inhibition and anticonvulsant activity in a model of generalised seizure in the rat. Epilepsy Research 2009; 85: 96-106
    CrossrefPubMedGoogle Scholar
  • 6 Wolfgang Löscher. Pharmacological effects and mechanisms of action. In-Mile stones in drug therapy Valproate. Ed: Loscher W. Indian Reprint. 2007: 7-45
    Google Scholar
  • 7 Wolfgang Löscher. Pharmacological effects and mechanisms of action. In-Mile stones in drug therapy Valproate. Ed: Loscher W. Indian Reprint 2007: 7-45
    Google Scholar
  • 8 Sullivan JE, Dlugos DJ. Idiopathic Generalized Epilepsy. Current treatment options in neurology 2004; May 6 (03) 231-242 PubMed PMID: 15043806.
    CrossrefPubMedGoogle Scholar
  • 9 Patsalos PN. Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. Epilepsia 2005; 46 (Suppl (09) 140-148 PubMed PMID: 16302888.
    CrossrefPubMedGoogle Scholar
  • 10 Marson AG, Al-Kharusi AM, Alwaidh M, Appleton R, Baker GA, Chadwick DW. et al. The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: An unblinded randomised controlled trial. Lancet 2007; Mar 24 369 9566 1016-1026 PubMed PMID: 17382828. Pubmed Central PMCID: 2039891.
    CrossrefPubMedGoogle Scholar
  • 11 Covanis A, Gupta AK, Jeavons PM. Sodium valproate: Monotherapy and poly-therapy. Epilepsia 1982; Dec 23 (06) 693-720 PubMed PMID: 6816580.
    CrossrefPubMedGoogle Scholar
  • 12 Karceski S, Morrell MJ, Carpenter D. Treatment of epilepsy in adults: Expert opinion. 2005; Epilepsy & behavior: E&B 2005; Sep 7 Suppl (01) S1-S64 quiz S5-7. PubMed PMID: 16102515.
    PubMedGoogle Scholar
  • 13 Trinka E, Marson AG, Van Paesschen W, Kalviainen R, Marovac J, Duncan B. et al. KOMET: An unblinded, randomised, two parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. Journal of neurology neurosurgery and psychiatry 2013; Oct 84 (10) 1138-1147 PubMed PMID: 22933814.
    CrossrefPubMedGoogle Scholar
  • 14 Bourgeois B, Beaumanoir A, Blajev B, de la Cruz N, Despland PA, Egli M. et al. Monotherapy with valproate in primary generalized epilepsies. Epilepsia 1987; 28 Suppl (02) S8-S11 PubMed PMID: 3121293.
    CrossrefPubMedGoogle Scholar
  • 15 Rowan AJ, Meijer JW, de Beer-Pawlikowski N, van der Geest P, Meinardi H. Valproate-ethosuximide combination therapy for refractory absence seizures. Archives of neurology 1983; Dec 40 (13) 797-802 PubMed PMID: 6416232.
    CrossrefPubMedGoogle Scholar
  • 16 Ferrie CD, Robinson RO, Knott C, Panayiotopoulos CP. Lamotrigine as an add-on drug in typical absence seizures. Acta neurologica Scandinavica 1995; Mar 91 (03) 200-202 PubMed PMID: 7793236.
    PubMedGoogle Scholar
  • 17 Berkovic SF, Andermann F, Guberman A, Hipola D, Bladin PF. Valproate prevents the recurrence of absence status. Neurology 1989; Oct 39 (10) 1294-1297 PubMed PMID: 2507956.
    CrossrefPubMedGoogle Scholar
  • 18 Marson AG, Williamson PR, Clough H, Hutton JL, Chadwick DW. Epilepsy Mono-therapy Trial G. Carbamazepine versus valproate monotherapy for epilepsy: a meta-analysis. Epilepsia 2002; May 43 (05) 505-513 PubMed PMID: 12027911.
    CrossrefPubMedGoogle Scholar
  • 19 Verrotti A, Grosso S, D'Egidio C, Parisi P, Spalice A, Pavone P. et al. Valproate in adolescents with photosensitive epilepsy with generalized tonic-clonic seizures only. European journal of paediatric neurology: EJPN: official journal of the European Paediatric Neurology Society 2014; Jan 18 (01) 13-18 PubMed PMID: 23891468.
    CrossrefPubMedGoogle Scholar
  • 20 Guerrini R. Valproate as a mainstay of therapy for pediatric epilepsy. Paediatr Drugs 2006; 8: 113-129
    CrossrefPubMedGoogle Scholar
  • 21 Loscher W, Honack D. Valproate and its major metabolite E-2-envalproate induce different eff ects on behaviour and brain monoamine metabolism in rats. Eur J Pharmacol 1996; 299: 61-67
    CrossrefPubMedGoogle Scholar
  • 22 Barry JJ. The Recognition and Management of Mood Disorders as a Comorbidity of Epilepsy. Epilepsia 2003; 44 S4 30-40
    PubMedGoogle Scholar
  • 23 Klapper J. Divalproex sodium in migraine prophylaxis: A dose controlled study. Cephalalgia 1997; 17: 103-108
    CrossrefPubMedGoogle Scholar
  • 24 Freitag FG, Collins SD, Carlson HA. et al. A randomized trial of divalproex sodium extended-release tablets in migraine prophylaxis. Neurology 2002; 58: 1652-1659
    CrossrefPubMedGoogle Scholar
  • 25 Yılmaz U, Yılmaz TS, Akıncı G, Korkmaz HA, Tekgül H. The effect of antiepileptic drugs on thyroid function in children. Seizure 2014; 23: 29-35
    CrossrefPubMedGoogle Scholar
  • 26 Pylvanen V, Pakarinen A, Knip M, Isojarvi J. Characterization of insulin secretion in Valproate-treated patients with epilepsy. Epilepsia 2006; 47: 1460-1464
    CrossrefPubMedGoogle Scholar
  • 27 Morrell MJ, Hayes FJ, Sluss PM. et al. Hyperandrogenism, ovulatory dysfunction and polycystic ovary syndrome with valproate versus lamotrigine. Ann Neurol 2008; 64: 200-211
    CrossrefPubMedGoogle Scholar
  • 28 Knorr M, Schaper J, Harjes M. et al. Fanconi syndrome caused by antiepileptic therapy with valproic acid. Epilepsia 2004; 45: 868-871
    CrossrefPubMedGoogle Scholar
  • 29 Yacoob Y, Bhigjee AL, Moodley P, Parboosing R. Valproate and highly active antiretroviral therapy in HIV positive patients who develop new onset seizures. Seizure 2011; 20: 80-82
    CrossrefPubMedGoogle Scholar
  • 30 Hsieh CY, Lai EC, Yang YH, Lin SJ. Comparative stroke risk of antiepileptic drugs in patients with epilepsy. Epilepsia 2013; 54: 172-180
    CrossrefPubMedGoogle Scholar
  • 31 Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol 2006; Mar 61: 246-255
    CrossrefPubMedGoogle Scholar
  • 32 Acharya S, Bussel JB. Hematologic toxicity of valproate. J Pediatr Hematol Oncol 2000; 22: 62-65
    CrossrefPubMedGoogle Scholar
  • 33 Murthy J. Tuberculous meningitis: The challenges. Neurol India 2010; 58: 716-722
    CrossrefPubMedGoogle Scholar
  • 34 Pohlmann-Eden B, Peters CN, Wennberg R, Dempfle CE. Valproate induces reversible factor XIII deficiency with risk of perioperative bleeding. Acta Neurol Scand 2003; 108: 142-145
    CrossrefPubMedGoogle Scholar
  • 35 Anderson GD, Lin YX, Berge C, Ojemann GA. Absence of bleeding complications in patients undergoing cortical surgery while receiving valproate treatment. J Neurosurg 1997; 87 (02) 252-256
    CrossrefPubMedGoogle Scholar